

IN THE CLAIMS

1. (Currently Amended) A method of inhibiting inflammation ~~by administration of a antibodies or antigen binding fragments in a mammal in need thereof, comprising administering to said mammal a composition comprising:~~
 - a) an antibody which binds at least one binds to a mammalian chemokine, and
 - b) a pharmaceutically acceptable carrier;
~~chosen from wherein said chemokine is selected from the group consisting of: CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10 by administration to a mammal in need of anti inflammatory intervention, of an inflammation-inhibiting effective amount of said antibodies in a pharmaceutically acceptable carrier.~~
2. (Currently Amended) The method of Claim 1, wherein the carrier is a liquid.
3. (Currently Amended) The method of Claim 1, wherein said mammal is a human.
4. (Currently Amended) The method of Claim 1, wherein the carrier is a solid support.
5. (Currently Amended) The method of Claim 1, wherein said ~~antibodies or antigen binding fragments are derived from a antibody is a human, humanized, or chimeric antibody.~~
6. (Currently Amended) The method of Claim 1, wherein said ~~antibodies or antigen binding fragments are composition is administered directly to an inflamed tissue showing an inflammatory response tissue.~~

7. (Currently Amended) A method of treating a mammal with inflammatory disease by
~~the steps of comprising:~~

- 1a) exposing tissues from said mammal to ~~differing~~ antibodies which bind to specific chemokines,
- 2b) identifying level of expression of each chemokine based on binding of the each of ~~the differing antibodies~~ said antibodies, and
- 3c) administering to said mammal ~~those at least one antibody specific anti bodies which bind to the for an over-expressed chemokines chemokine, wherein said chemokine is selected from the group consisting of: CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10.~~

8. (Currently Amended) The method of Claim 7, wherein[[,]] in step [[3]]c, ~~the antibodies are~~ said antibody is administered directly to the affected tissue.

9. (Currently Amended) The method of Claim 7, wherein[[,]] in step [[3]]c, ~~the antibodies are~~ said antibody is administered parenterally.

10. (Currently Amended) The method of Claim 7, wherein ~~the antibodies are~~ said antibody is administered in a liquid carrier.

11. (Currently Amended) The method of Claim 7, wherein ~~the antibodies are~~ said antibody is administered on a solid support.

12. (Currently Amended) A method of treating a mammal with inflammatory disease by the steps of:

- 1a) identifying the level of particular chemokines using PCR,
- 2b) administering to said mammal ~~those at least one antibody specific specifically anti-bodies which bind binds to an over-expressed chemokines in a pharmaceutically acceptable carrier chemokine, wherein said chemokine is selected from the group consisting of: CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10.~~

13. (Currently Amended) The method of Claim 12, wherein ~~the antibodies are said antibody~~ is administered directly to the affected tissue.

14. (Currently Amended) The method of Claim 12, wherein ~~the antibodies are said antibody~~ is administered systemically.

15. (Currently Amended) The method of Claim 12, wherein ~~the antibodies are said antibody~~ is administered on a solid support.

16. (Canceled)

17. (New) The method of Claim 1, wherein said antibody is specific for CXCL10.

18. (New) The method of Claim 7, wherein said antibody is specific for CXCL10.

19. (New) The method of Claim 12, wherein said antibody is specific for CXCL10.